Rhumbline Advisers Avidity Biosciences, Inc. Transaction History

Rhumbline Advisers

$109 Billion
Q3 2024

A detailed history of Rhumbline Advisers transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 149,008 shares of RNA stock, worth $4.42 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

149,008

Previous 141,481 5.32%

Holding current value

$4.42 Million

Previous $5.78 Million 18.41%

% of portfolio

0.01%

Previous 0.01%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$37.21 - $48.14 $280,079 - $362,349	7,527 Added 5.32%	149,008 $6.84 Million
Q2 2024 Aug 01, 2024	BUY	$22.73 - $40.85 $513,788 - $923,373	22,604 Added 19.01%	141,481 $5.78 Million
Q1 2024 May 09, 2024	BUY	$9.16 - $25.52 $37,647 - $104,887	4,110 Added 3.58%	118,877 $3.03 Million
Q4 2023 Feb 08, 2024	BUY	$4.87 - $9.37 $21,087 - $40,572	4,330 Added 3.92%	114,767 $1.04 Million
Q3 2023 Nov 09, 2023	SELL	$6.3 - $11.35 $3,055 - $5,504	-485 Reduced 0.44%	110,437 $704,000
Q2 2023 Aug 08, 2023	BUY	$10.62 - $17.34 $146,821 - $239,725	13,825 Added 14.24%	110,922 $1.23 Million
Q1 2023 May 11, 2023	BUY	$15.35 - $25.65 $255,500 - $426,944	16,645 Added 20.69%	97,097 $1.49 Million
Q4 2022 Feb 14, 2023	BUY	$10.06 - $22.66 $32,161 - $72,444	3,197 Added 4.14%	80,452 $1.79 Million
Q3 2022 Nov 10, 2022	BUY	$15.46 - $23.43 $121,762 - $184,534	7,876 Added 11.35%	77,255 $1.26 Million
Q2 2022 Aug 11, 2022	BUY	$11.18 - $20.5 $259,923 - $476,604	23,249 Added 50.4%	69,379 $1.01 Million
Q1 2022 May 12, 2022	BUY	$14.2 - $23.78 $27,434 - $45,942	1,932 Added 4.37%	46,130 $852,000
Q4 2021 Feb 10, 2022	BUY	$20.4 - $28.66 $32,109 - $45,110	1,574 Added 3.69%	44,198 $1.05 Million
Q3 2021 Nov 12, 2021	BUY	$18.16 - $25.21 $92,852 - $128,898	5,113 Added 13.63%	42,624 $1.05 Million
Q2 2021 Aug 05, 2021	BUY	$19.62 - $29.26 $137,045 - $204,381	6,985 Added 22.88%	37,511 $927,000
Q1 2021 May 06, 2021	BUY	$20.28 - $28.15 $227,419 - $315,674	11,214 Added 58.07%	30,526 $666,000
Q4 2020 Feb 10, 2021	BUY	$24.73 - $35.12 $44,415 - $63,075	1,796 Added 10.25%	19,312 $493,000
Q3 2020 Nov 12, 2020	BUY	$23.35 - $35.94 $408,998 - $629,525	17,516 New	17,516 $493,000

Others Institutions Holding RNA

# of Institutions

252

Shares Held

107M

Call Options Held

224K

Put Options Held

161K

View Full List

About Avidity Biosciences, Inc.

Ticker RNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,127,000
Market Cap $1.55B
Description
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...

More about RNA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Avidity Biosciences, Inc. Transaction History